Literature DB >> 2464056

Epitope characterization of acetaminophen bound to protein and nonprotein sulfhydryl groups by an enzyme-linked immunosorbent assay.

D W Potter1, N R Pumford, J A Hinson, R W Benson, D W Roberts.   

Abstract

The oxidation of acetaminophen to N-acetyl-p-benzoquinone imine and its subsequent binding to protein sulfhydryl groups may be important in the observed toxicity of acetaminophen. An avidin biotin-amplified competitive enzyme-linked immunosorbent assay has been developed which utilizes solid phase acetaminophen bound to metallothionein and antiserum obtained from rabbits that were immunized with 3-(N-acetyl-L-cystein-S-yl)acetaminophen covalently bound to keyhole-limpet hemocyanin. Over 25 synthetic analogs of acetaminophen conjugates and structurally similar compounds have been ranked relative to their ability to compete in the avidin biotin-amplified enzyme-linked immunosorbent assay. The most effective inhibitor was 3-(N-acetyl-L-cystein-S-yl)acetaminophen, which had an observed 50% inhibitory concentration of 120 fmol/well. Approximately 6200-fold higher concentrations of unbound acetaminophen and 5.2 x 10(6)-fold higher concentrations of N-acetyl-L-cysteine were required for comparable inhibition. It was demonstrated with acetaminophen analogs that the hydroxyl group and the N-acetyl moiety of acetaminophen were important in epitope recognition. A 5000-fold decrease in detection was observed when the analog did not contain the hydroxyl group or when the N-acetyl moiety was replaced with a hydroxyl substituent. Recognition by antibody was also dependent upon the stereochemistry of the analogs. The 50% inhibitory concentration for 3-(L-cystein-S-yl)acetaminophen was 2300 fmol/well, whereas a 25-fold higher concentration of 3-(D-cystein-S-yl)acetaminophen was required for 50% inhibition.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2464056

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

1.  An Immunoassay to Rapidly Measure Acetaminophen Protein Adducts Accurately Identifies Patients With Acute Liver Injury or Failure.

Authors:  Dean W Roberts; William M Lee; Jack A Hinson; Shasha Bai; Christopher J Swearingen; R Todd Stravitz; Adrian Reuben; Lynda Letzig; Pippa M Simpson; Jody Rule; Robert J Fontana; Daniel Ganger; K Rajender Reddy; Iris Liou; Oren Fix; Laura P James
Journal:  Clin Gastroenterol Hepatol       Date:  2016-09-15       Impact factor: 11.382

2.  A novel defensive mechanism against acetaminophen toxicity in the mouse lateral nasal gland: role of CYP2A5-mediated regulation of testosterone homeostasis and salivary androgen-binding protein expression.

Authors:  Xin Zhou; Yuan Wei; Fang Xie; Christina M Laukaitis; Robert C Karn; Kerri Kluetzman; Jun Gu; Qing-Yu Zhang; Dean W Roberts; Xinxin Ding
Journal:  Mol Pharmacol       Date:  2011-01-20       Impact factor: 4.436

3.  Cooperativity in CYP2E1 metabolism of acetaminophen and styrene mixtures.

Authors:  Jessica H Hartman; Lynda G Letzig; Dean W Roberts; Laura P James; E Kim Fifer; Grover P Miller
Journal:  Biochem Pharmacol       Date:  2015-07-28       Impact factor: 5.858

4.  Immunohistochemical localization and quantification of the 3-(cystein-S-yl)-acetaminophen protein adduct in acetaminophen hepatotoxicity.

Authors:  D W Roberts; T J Bucci; R W Benson; A R Warbritton; T A McRae; N R Pumford; J A Hinson
Journal:  Am J Pathol       Date:  1991-02       Impact factor: 4.307

Review 5.  Translational biomarkers of acetaminophen-induced acute liver injury.

Authors:  Richard D Beger; Sudeepa Bhattacharyya; Xi Yang; Pritmohinder S Gill; Laura K Schnackenberg; Jinchun Sun; Laura P James
Journal:  Arch Toxicol       Date:  2015-05-17       Impact factor: 5.153

Review 6.  Biomarkers of drug-induced liver injury: a mechanistic perspective through acetaminophen hepatotoxicity.

Authors:  David S Umbaugh; Hartmut Jaeschke
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-12-09       Impact factor: 3.869

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.